Related Experiment Videos
[In vivo antibacterial activity of cefoperazone in intraperitoneal infections in mice]
Abstract:
The in vivo antibacterial activity of cefoperazone (CPZ) against systemic infections was studied in comparison with that of cefotiam (CTM) using beta-lactamase non-producing bacteria and producing bacteria. In vitro antibacterial activity of CPZ against Gram-positive bacteria was slightly inferior to that of CTM, but there was no significant difference between their in vivo activities. On the other hand, the therapeutic effect of CPZ against Gram-negative bacteria was nearly parallel to in vitro antibacterial activity and particularly was superior to that of CTM against cephalosporinase (CSase) producing bacteria. The ascitic levels of CPZ in mice infected with CSase producing bacteria were persisted longer, but those of CTM disappeared quickly after administration. This result appeared to reflect on the therapeutic effects of both drugs.
Insights
Cefoperazone (CPZ) shows comparable in vivo antibacterial activity to cefotiam (CTM) against systemic infections. CPZ is particularly effective against Gram-negative bacteria producing cephalosporinase, with longer persistence in mice.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing concern in treating bacterial infections.
- Beta-lactamase producing bacteria pose a significant challenge to existing therapies.
- Understanding the comparative efficacy of antibiotics is crucial for effective treatment strategies.
Purpose of the Study:
- To compare the in vivo antibacterial activity of cefoperazone (CPZ) and cefotiam (CTM).
- To evaluate the efficacy against both beta-lactamase non-producing and producing bacteria.
- To investigate the pharmacokinetic profile influencing therapeutic outcomes.
Main Methods:
- In vivo assessment of antibacterial activity in systemic infections.
- Comparison of cefoperazone and cefotiam against Gram-positive and Gram-negative bacteria.
- Evaluation of drug persistence in murine models with cephalosporinase-producing bacteria.
Main Results:
- In vitro, cefoperazone showed slightly lower activity against Gram-positive bacteria than cefotiam, but in vivo activity was comparable.
- Cefoperazone demonstrated superior in vivo efficacy against Gram-negative bacteria, especially those producing cephalosporinase.
- Cefoperazone exhibited prolonged persistence in ascitic fluid compared to cefotiam in mice infected with cephalosporinase-producing bacteria.
Conclusions:
- Cefoperazone offers a valuable therapeutic option for systemic infections caused by Gram-negative bacteria, including cephalosporinase producers.
- The enhanced persistence of cefoperazone contributes to its superior therapeutic effect in specific infections.
- Comparative pharmacokinetic and pharmacodynamic studies are essential for optimizing antibiotic selection.